Adalimumab and dexamethasone for treating non-infectious uveitis – guidance (TA460)

Adalimumab is recommended as an option for treating non-infectious uveitis in the posterior segment of the eye in adults with inadequate response to corticosteroids, providing certain criteria are met.

These criteria include the following: 

• active disease (that is, current inflammation in the eye) and
• inadequate response or intolerance to immunosuppressants and
• systemic disease or both eyes are affected (or 1 eye is affected if the second eye has poor visual acuity) and
• worsening vision with a high risk of blindness (for example, risk of blindness that is similar to that seen in people with macular oedema).